Skip to content

RayStation 9B SP1

by RaySearch Laboratories AB (PUBL)

Ref 9.2

RayStation 9B SP1 is a device classified as Class IIb in the EU and Class II in the US made by RaySearch Laboratories AB (PUBL), registered in EUDAMED on 27 Oct 2026 (Basic UDI-DI B-07350002010297), cleared under FDA 510(k) K200569 on 24 Sep 2020 and listed in FDA GUDID since 27 May 2021 (UDI-DI 07350002010297), active as of 7 Nov 2026. 14 FDA recalls are linked to it.

Active European Union and United States. Also listed in GUDID (US).

CE MDD 510(k)

Valid until

No date given

CE: no date in EUDAMED. FDA: not time-limited

FDA recalls

6 ongoing

This device is named in the recall

Documents

None linked in EUDAMED

A group certificate may exist

510(k) K200569

FDA submission, from GUDID

Trust

Unverified

Source EUDAMED, GUDID, synced 7 Nov 2026.

Regulatory status

as of registry sync 7 Nov 2026

RegionAuthorizationNumberDateStatus
European UnionCE/MDD EUDAMED NumberB-07350002010297 Basic UDI-DI 07350002010297UDI-DIDate27 Oct 2026RegisteredStatusActive
United StatesGUDID listing GUDID Number07350002010297 UDI-DI Date27 May 2021ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k)SESE GUDID from GUDID Substantially Equivalent · Traditional NumberK200569 Date24 Sep 2020DecidedStatusActive

Official records

Across registries

3 registries list this device

  • EUDAMED Basic UDI-DI B-07350002010297 registered 27 Oct 2026 Active
  • FDA 510(k) K200569 decided 24 Sep 2020 Active
  • FDA GUDID UDI-DI 07350002010297 listed 27 May 2021 Listed

Recalls

14 recalls · 6 ongoing · FDA

    • Ongoing Z-2489-2025 FDA Class II initiated 8 Aug 2025

    DICOM SOP Instance UID and Series Instance UID from RayGateway, i.e. the interface to Accuray's iDMS, are not guaranteed to be unique.

    • Ongoing Z-1187-2025 FDA Class II initiated 16 Jan 2025

    Inconsistency in the use of Density uncertainty in the RayStation functions Robust optimization, Robust evaluation and Compute perturbed dose for proton and light ion treatment plans when a HU-to-mass density CT calibration curve used in RayStation version 4.5 to 2024B including some service packs.

  • 2 recalls, same reason

    • Ongoing Z-1745-2024 FDA Class II initiated 28 Mar 2024
    • Ongoing Z-1746-2024 FDA Class II initiated 28 Mar 2024

    Potential for reported SSD to be too high.

    • Ongoing Z-1482-2024 FDA Class II initiated 23 Feb 2024

    A use error that has occurred with RayStation/RayPlan, where material override using Silicon, Si, was incorrectly selected for a silicone gel polymer implant.

    • Ongoing Z-1427-2021 FDA Class II initiated 25 Mar 2021

    Flags edited in RayCare after a patient has been checked in may not always be updated in RayTreat.

    • Terminated Z-1403-2022 FDA Class II initiated 1 Jun 2022

    An issue with propagation of treatment course information from RayStation with RayTreat to RayCare has been identified. During some workflows, information may not be propagated to RayCare.

    • Terminated Z-2138-2021 FDA Class II initiated 8 Jun 2021

    Initial delivery positions will be set incorrectly when having setup beam(s) at the localization point.

    • Terminated Z-1838-2021 FDA Class II initiated 21 Apr 2021

    Evaluation of a clinical goal for the voxelwise worst dose distributions may be misleading after editing the clinical goal. It also describes an issue with contouring when the spacing between slices is d 1 mm, present in RayStation/RayPlan versions from 6 up to 10A.

    • Terminated Z-1598-2021 FDA Class II initiated 7 Apr 2021

    When using more than one plan in a treatment course, the Total dose display in Dose tracking may be incorrect. There may be a mismatch between the fractions that appear as selected in the Treatment course list in Dose tracking and the fractions that are included in the dose summation. The issue only affects RayTreat users and only the Total dose option. Accumulation and other options in Dose tracking are correct.

    • Terminated Z-1597-2021 FDA Class II initiated 22 Feb 2021

    For some LINAC types, merging clinical beams with beams of approximate dose may lead to the approximate dose erroneously labeled as clinical dose. Merge beams can be used manually, in scripting, or as part of the Automated breast planning feature. In some cases, when merging two beams where the first beam has clinical dose and the second beam has approximate dose, the dose of the resulting beam will be labeled as Clinical, although dose for some of the beam segments is still calculated with the SVD dose engine and it should be labeled Approximate: Mixed dose. The difference between approximate and final Clinical dose is in most cases small, but there can be body sites such as lung where the difference can be significant.

    • Terminated Z-2039-2023 FDA Class II initiated 22 Jan 2021

    A software bug affecting results when using deep learning (DL) segmentation followed by geometrical functions: Create wall function, Expand Contract function or ROI algebra function, the results are incorrect. If dose statistics for an incorrectly created ROI are used to determine if a plan is acceptable for treatment, this could potentially lead to an inappropriate plan being approved. The error could lead to a more conservative or more liberal plan than intended.

    • Terminated Z-0589-2021 FDA Class II initiated 11 Nov 2020

    Two issues were found with the treatment plan report: 1) There may be incorrect information for the percent of a region of interest with a clinical goal that is outside the dose grid; and 2) For RayStation and RayPlan 9B and 10A, 6D couch angles may be incorrect.

    • Terminated Z-0478-2021 FDA Class II initiated 8 Oct 2020

    If a region of interest (ROI) or point of interest (POI) that is referenced from an imported plan is missing in the imported RT Structure Set, the reference may become linked to the wrong ROI or POI.

Timeline

17 dated events

  1. Recall initiated FDA recalls Z-1838-2021
  2. Listed FDA GUDID 07350002010297
  3. Recall initiated FDA recalls Z-2138-2021
  4. Recall initiated FDA recalls Z-1403-2022
  5. Recall initiated FDA recalls Z-1482-2024
  6. Recall initiated FDA recalls Z-1745-2024
  7. Recall initiated FDA recalls Z-1746-2024
  8. Recall initiated FDA recalls Z-1187-2025
  9. Recall initiated FDA recalls Z-2489-2025
  10. Registered EUDAMED B-07350002010297

7 earlier events are in the sections above.

Coverage

2 jurisdictions

United States of AmericaSwedenFinlandLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaAustriaHungaryRomaniaSloveniaBulgariaPortugalSpainItalyCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered
  • European Union CE/MDD Active
  • United States FDA 510(k) Active

Specification

EUDAMED · GUDID

Trade name
RayStation 9B SP1 EUDAMED
RayStation GUDID
Generic name
Radiation therapy software
Model / reference
9.2 EUDAMED
9B SP1 GUDID
Primary DI / UDI-DI
07350002010297
Basic UDI-DI
B-07350002010297
510(k) Number
FDA product code
MUJ
EMDN code
Z11019082 Various radiotherapy and radiosurgery instruments - software accessories
GMDN term
Radiation therapy software
Device class
Class IIb EUDAMED
Class II GUDID
Regulation number
892.5050
System or procedure pack
System which is a device in itself
EU registration type
Legacy device (under a directive)
EU market of registration
Belgium
GUDID distribution status
In Commercial Distribution

Truth per registry

2 sources · 2 fields differ

FieldEUDAMEDGUDID
Model / referenceEUDAMED
9.2
GUDID
9B SP1
Device classEUDAMED
Class IIb
GUDID
Class II

Device class is stated on each registry's own scale: Class IIb in the EU (EUDAMED), Class II in the US (FDA GUDID). EU and US classes are different schemes, so this is not a disagreement.

Similar devices in this category

Other devices filed under VARIOUS RADIOTHERAPY AND RADIOSURGERY INSTRUMENTS.

Other devices from RaySearch Laboratories AB (PUBL)

See all devices from RaySearch Laboratories AB (PUBL) →

Properties

  • Serial number
  • Manufacturing date
Other properties (21, all answered No)